Use of CDR-sob and ADAS-cog score to check protective role of Non-steroidal AntiInflammatory Drugs in Alzheimer Disease: A Systematic Review and Meta-Analysis

Abstract

Background Alzheimer’s disease is the major neurodegenerative disease, affecting more than two third cases
of dementia in the world. NSAIDs are widely used anti-inflammatory analgesic agents representing 7.7% of
worldwide prescription of which 90% are in patients over 65 year old. Based on mixed findings by different
RCTs, a systematic review and meta-analysis on CDR-sob and ADAS-cog score was conducted to develop
the better understanding on the protective role of Non-steroidal anti inflammatory drugs (NSAIDs) in AD.
Methods Data base search was Pubmed, WebScience and Embase. RCTs investigating the effect of NSAIDs
on AD or test scores assessing cognitive function in people without AD at baseline were included. Two
indicators ADAS-cog score, and CDR-sob are used. Total 09 studies are included in the present Metaanalysis.
Results
For
ADAS-score
pooled
the
pooled
summary
effect
size
was
calculated
using
random
effect

model
was
-0.03
with
95%
C.I
-0.13
to
0.07,
which
was
statistically
insignificant
(p-value
=0.44).
For
CDRsob

score difference, the pooled the pooled summary effect size was calculated using random effect model
was -0.09 with 95% C.I -0.29 to 0.11 which was statistically insignificant (p=0.3812).For CDR-sob score, the
pooled summary effect size was calculated using random effect model was 0.21 with 95% C.I -0.09 to 0.51,
which was statistically insignificant (p-value = 0.1741). Conclusion Present Meta analysis shows that
NSAIDs in general are not effective in treatment of AD. They also have no protective effect against
development of AD on their sustained use.